Published in Immunotherapy Weekly, April 6th, 2005
According to a study from Switzerland, "Immunotherapy is being proposed to treat patients with hepatocellular carcinoma (HCC). However, more detailed knowledge on tumor antigen expression and specific immune cells is required for the preparation of highly targeted vaccines. HCC express a variety of tumor-specific antigens, raising the question whether CTL specific for such antigens exist in HCC patients. Indeed, a recent study revealed CTLs specific for two cancer-testis (CT) antigens (MAGE-A1 and MAGE-A3) in tumor infiltrating...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.